文献速递细菌感染、耐药与抗菌药物

一项减少医院抗生素过度使用的国家质量激励计划:对认知与影响的评估

A national quality incentive scheme to reduce antibiotic overuse in hospitals: evaluation of perceptions and impact.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

2016/2017年英格兰急性医院实施与经费挂钩的抗菌药物处方质量改进计划(AMR-CQUIN),目标为总抗生素、哌拉西林/他唑巴坦和碳青霉烯类DDD/1000入院数较2013/2014年降低>1%并改善经验性处方审核。调查116/155(75%)急性医院抗菌药物管理负责人,多数医院因抗生素使用逐年增加需降低>5%才能达标;23/113(20%)医院获得额外资金,其中18家(78%)低于AMR-CQUIN价值的10%。全国抗生素使用年增长趋势在2016/2017年逆转,认为可减少抗生素使用的医院更可能实现减少(P<0.001)。

要点

  • 116/155(75%)急性医院应答,多数需降低>5%才能达到AMR-CQUIN的1%降幅目标。
  • 23/113(20%)医院获得额外资金,其中18家(78%)低于AMR-CQUIN价值的10%。
  • 全国抗生素使用年增长趋势在2016/2017年逆转,认为可减少使用的医院更可能减少(P<0.001)。

核心结论

  • 引入AMR-CQUIN与抗生素使用减少相关;对单个医院而言,达标与工作人员的良好认知相关,而非与资金可得性相关。

研究设计与样本

  • 邀请英格兰急性医院抗菌药物管理负责人完成网络调查,抗生素处方数据来自PHE Antimicrobial Resistance Local Indicators资源。
  • 应答来自116/155(75%)急性医院。

主要发现

  • 由于抗生素使用逐年增加,多数信托需将抗生素消耗降低>5%才能实现AMR-CQUIN的1%降幅目标。
  • 23/113(20%)信托获得额外资金,其中18家(78%)低于AMR-CQUIN价值的10%。
  • 全国抗生素使用年增长趋势在2016/2017年逆转。
  • 2014/2015年同比变化:总抗生素+3.7%(IQR -0.8%, +8.4%),哌拉西林/他唑巴坦+9.4%(+0.2%, +19.5%),碳青霉烯类+5.8%(-6.2%, +18.2%)。
  • 2016/2017年同比变化:总抗生素+0.1%(-5.4%, +4.0%),哌拉西林/他唑巴坦-4.8%(-16.9%, +3.2%),碳青霉烯类-8.0%(-20.2%, +4.0%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2016/2017, a financially linked antibiotic prescribing quality improvement initiative Commissioning for Quality and Innovation (AMR-CQUIN) was introduced across acute hospitals in England. This aimed for >1% reductions in DDDs/1000 admissions of total antibiotics, piperacillin/tazobactam and carbapenems compared with 2013/2014 and improved review of empirical antibiotic prescriptions. OBJECTIVES: To assess perceptions of staff leading antimicrobial stewardship activity regarding the AMR-CQUIN, the investments made by hospitals to achieve it and how these related to achieving reductions in antibiotic use. METHODS: We invited antimicrobial stewardship leads at acute hospitals across England to complete a web-based survey. Antibiotic prescribing data were downloaded from the PHE Antimicrobial Resistance Local Indicators resource. RESULTS: Responses were received from 116/155 (75%) acute hospitals. Owing to yearly increases in antibiotic use, most trusts needed to make >5% reductions in antibiotic consumption to achieve the AMR-CQUIN goal of 1% reduction. Additional funding was made available at 23/113 (20%) trusts and, in 18 (78%), this was <10% of the AMR-CQUIN value. Nationally, the annual trend for increased antibiotic use reversed in 2016/2017. In 2014/2015, year-on-year changes were +3.7% (IQR -0.8%, +8.4%), +9.4% (+0.2%, +19.5%) and +5.8% (-6.2%, +18.2%) for total antibiotics, piperacillin/tazobactam and carbapenems, respectively, and +0.1% (-5.4%, +4.0%), -4.8% (-16.9%, +3.2%) and -8.0% (-20.2%, +4.0%) in 2016/2017. Hospitals where staff believed they could reduce antibiotic use were more likely to do so (P < 0.001). CONCLUSIONS: Introducing the AMR-CQUIN was associated with a reduction in antibiotic use. For individual hospitals, achieving the AMR-CQUIN was associated with favourable perceptions of staff and not availability of funding.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Islam J, Ashiru-Oredope D, Budd E, et al. A national quality incentive scheme to reduce antibiotic overuse in hospitals: evaluation of perceptions and impact. J Antimicrob Chemother. 2018. PMID: 29506043. doi:10.1093/jac/dky041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。